![]() |
市場調查報告書
商品編碼
1401078
鞘內泵全球市場規模、佔有率和行業趨勢分析報告:2023-2030 年按應用、類型和地區分類的展望和預測Global Intrathecal Pumps Market Size, Share & Industry Trends Analysis Report By Application (Pain, and Spasticity), By Type (Morphine, Ziconotide, Baclofen, Bupivacaine, Clonidine, and Others), By Regional Outlook and Forecast, 2023 - 2030 |
到 2030 年,鞘內幫浦市場規模預計將達到 4.917 億美元,預測期內複合年成長率為 5.7%。
此外,COVID-19 大流行對市場產生了中等影響。在大流行的早期階段,許多選擇性手術和醫療程序被推遲或取消,包括與鞘內泵植入相關的手術和醫療程序。醫院和醫療機構面臨優先處理 COVID-19 病例的巨大壓力,導致非緊急手術的延遲。這種延遲影響了市場的成長軌跡。這是因為病人延後了擇期手術,影響了新入院和替代手術。疫情導致的全球供應鏈中斷影響了醫療設備和零件的可得性。這些泵浦和相關配件的製造商面臨原料採購、生產延誤和物流問題的挑戰。這些干擾導致市場波動,影響供需雙方。因此,由於這些變化,預計市場在未來幾年將顯著成長。
然而,由於龐大的初期成本,包括幫浦、手術植入和相關程序的成本,鞘內幫浦治療可能會造成財務障礙。保險不足或經濟能力有限的患者在獲得這種先進治療方法可能面臨挑戰。不一致或不充分的報銷政策可能會阻礙鞘內泵治療的廣泛普及。缺乏保險報銷或保險報銷率不足以支付與治療相關的費用可能會阻礙醫療保健提供者提供這種治療作為治療選擇。患者的經濟負擔可能導致患者醫囑遵從性性下降、不願意接受鞘內泵治療或可能停止治療。由於上述方面,預計未來幾年市場成長將下降。
按用途分類的展望
根據應用,市場分為痙攣和疼痛。 2022 年,痙攣細分市場在市場中佔據了重要的收益佔有率。巴氯芬等藥物直接給藥脊髓。巴氯芬是一種肌肉鬆弛劑,作用於中樞神經系統以減輕痙攣。標靶化使藥物在作用部位的濃度更合適,從而更好地控制肌張力和痙攣。透過鞘內幫浦治療控制痙攣可以改善肌肉功能和活動範圍。這使得物理治療和復健更加有效,並提高整體運動能力和功能。
按類型分類的展望
依類型分類,市場分為巴氯芬、布比卡因、可樂定、嗎啡、齊考諾肽等。 2022年,嗎啡細分市場以最大的收益佔有率主導市場。嗎啡因其強大的受體親和性、穩定的性能和廣泛的用戶知識而成為鞘內給藥的基準。此外,嗎啡已獲得美國FDA 核准作為長期鞘內疼痛治療藥物。此外,與全身性鴉片類藥物相比,長期鞘內注射嗎啡副作用較少,預計將刺激該細分市場的成長。據世界衛生組織稱,嗎啡等鴉片類藥物經常被處方,因為它們能夠緩解不適。鴉片類藥物可有效緩解從急性到慢性的各種疼痛。鴉片類藥物透過作用於大腦和脊髓中的特定受體來減少疼痛訊號。
區域展望
從區域來看,我們對北美、歐洲、亞太地區和拉丁美洲地區的市場進行了分析。 2022年,北美地區的收益佔有率最高。設備齊全的初級、二級和三級醫療機構的存在促進了北美市場的成長。此外,有利的政府津貼和強大的報銷網路預計將推動市場擴張。主要市場參與企業不斷加強合作,以增強其產品線並確保卓越的質量,預計將刺激該地區對鞘內泵的需求。美國癌症發生率不斷上升,推動了對先進有效鞘內泵的需求不斷成長。
The Global Intrathecal Pumps Market size is expected to reach $491.7 million by 2030, rising at a market growth of 5.7% CAGR during the forecast period.
Bupivacaine is regarded as an exceptional adjunctive drug in intrathecal therapy. Thus, the Bupivacaine segment acquired $36,149.5 thousand in 2022. The synergistic enhancement of intrathecal opioid effects when bupivacaine is combined with them has been demonstrated in multiple studies, which has contributed significantly to its expanding market share. Bupivacaine reduces dose escalations of intrathecal opioids and permits some patients to reduce their oral opioid utilization. Thus, it is envisaged that several benefits associated with bupivacaine will sustain segment expansion. Some of the factors impacting the market are technological advancements in pump design, expanding applications in pain management and neurological disorders, and high initial costs and economic considerations.
Modern intrathecal pumps have advanced mechanisms that enable precise and accurate drug delivery. This precision is crucial for administering the proper medication dosage directly to the spinal cord, optimizing therapeutic effects while minimizing the risk of side effects. The integration of smart pump technologies has enhanced the capabilities of intrathecal pumps. These technologies often include remote monitoring, connectivity, and data analytics features. Healthcare providers can remotely monitor patient data, receive real-time alerts, and adjust the pump settings, improving overall patient care and management. Additionally, intrathecal pumps were initially developed for pain management, but their successful application has expanded to address a variety of neurological disorders, including spasticity, dystonia, and severe cases of Parkinson's disease. This diversification broadens the potential patient population benefitting from intrathecal pump therapy. Using these pumps in neurological disorders improves functionality and mobility in affected individuals. By directly targeting the underlying neurological mechanisms, these pumps help reduce muscle spasticity, dystonia, and other symptoms that can enormously impact a person's ability to move and perform daily activities. Healthcare teams comprising pain specialists, neurologists, and other relevant specialists collaborate to develop comprehensive treatment plans that address pain and associated neurological symptoms. Thus, the above-mentioned factors will expand the market growth.
Further, the COVID-19 pandemic moderately impacted the market. Many elective surgeries and medical procedures, including those related to intrathecal pump implantation, were postponed, or canceled during the initial phases of the pandemic. Hospitals and healthcare facilities were under immense pressure to prioritize COVID-19 cases, leading to delays in non-urgent procedures. This delay had influenced the market's growth trajectory, as patients defer elective surgeries, affecting both new installations and replacements. The global disruptions in supply chains caused by the pandemic have affected the availability of medical devices and components. Manufacturers of these pumps and related accessories faced challenges in procuring raw materials, production delays, and logistical issues. These disruptions contributed to fluctuations in the market, affecting both the supply and demand sides. As a result, due to these changes, the market is expected to grow significantly in the coming years.
However, the substantial upfront costs associated with intrathecal pump therapy, including the cost of the pump, surgical implantation, and related procedures, can create financial barriers to access. Patients without adequate insurance coverage or financial resources may face challenges accessing this advanced treatment option. Inconsistent or inadequate reimbursement policies can hinder the widespread adoption of intrathecal pump therapy. The lack of reimbursement or reimbursement rates that do not adequately cover the costs associated with the therapy may discourage healthcare providers from offering it as a treatment option. The financial burden on patients could lead to decreased patient adherence, reluctance to pursue intrathecal pump therapy or potential treatment discontinuation. Due to the above aspects, market growth is expected to decline in the coming years.
Application Outlook
Based on application, the market is fragmented into spasticity and pain. The spasticity segment garnered a significant revenue share in the market in 2022. It delivers medications, such as baclofen, directly to the spinal cord. Baclofen is a muscle relaxant that operates on the central nervous system to reduce spasticity. The targeted delivery allows for a more adequate concentration of the drug at its site of action, leading to better control of muscle tone and spasticity. Controlling spasticity through intrathecal pump therapy can improve muscle function and range of motion. This allows individuals to engage in physical therapy and rehabilitation more effectively, improving overall mobility and functionality.
Type Outlook
On the basis of type, the market is segmented into baclofen, bupivacaine, clonidine, morphine, ziconotide, and others. In 2022, the morphine segment dominated the market with the maximum revenue share. Morphine is the benchmark for intrathecal drug delivery due to its robust affinity for receptors, consistent performance, and substantial body of user knowledge. Furthermore, morphine has been granted sanction by the US FDA for the treatment of long-term intrathecal pain. Furthermore, compared to systemic opioids, long-term intrathecal morphine has fewer adverse effects, which is anticipated to stimulate the growth of this market segment. Owing to their ability to alleviate discomfort, opioids like morphine are frequently prescribed, per the WHO. They efficiently alleviate a wide range of pain, encompassing both acute and chronic ailments. Pain signals are diminished through the action of these medications on specific receptors in the brain and spinal cord.
Regional Outlook
Region-wise, the market is analyzed across North America, Europe, Asia Pacific, and LAMEA. In 2022, the North America region registered the highest revenue share in the market. The presence of adequately equipped primary, secondary, and tertiary care facilities bolstered growth in the North American market. In addition, favorable government funding and a robust reimbursement network are anticipated to drive market expansion. Expected to stimulate demand for intrathecal pumps in this region are the increasing collaborative efforts of key market participants to enhance their product lines and guarantee superior quality. An increased demand for sophisticated and effective intrathecal pumps is a result of the escalating incidence of cancer in the United States.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Medtronic plc, ICU Medical, Inc. (Smiths Medical), Teleflex, Inc., Johnson & Johnson (Johnson & Johnson Services, Inc.), Baxter International, Inc., Abbott Laboratories, Tricumed Medizintechnik GmbH, Flowonix Medical, Inc., Durect Corporation, and Novartis AG
Market Segments covered in the Report:
By Application
By Type
By Geography
Companies Profiled
Unique Offerings from KBV Research